Lentiviral vector containing VEGFR2 (vascular endothelial growth factor receptor 2) mutation, application of lentiviral vector in preparation of medicine for preventing and treating neovascular diseases and product

By introducing dominant negative VEGFR2 mutations into retinal microvascular endothelial cells, the lentiviral vector system blocks the VEGF/VEGFR2 signaling pathway, the problem of resistance of existing methods for treating neovascular diseases to some patients is solved, and angiogenesis is achieved Effective inhibition demonstrates innovative methods to combat angiogenic diseases.

CN118956969AActive Publication Date: 2024-11-15THE THIRD AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410912409.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-09
Publication Date
2024-11-15
Estimated Expiration
2044-07-09

AI Technical Summary

Technical Problem

The existing methods for treating neovascular diseases are resistant to some patients, especially anti-VEGF drugs and VEGFR2 kinase inhibitors have limited effects and are difficult to effectively inhibit angiogenesis.

Method used

A combination of lentiviral vectors containing VEGFR2 mutations was developed, through the fusion of Cas9 lyase and reverse transcriptase and dominant negative DNA mismatch repair proteins, VEGFR2 mutations were introduced to inhibit VEGF-induced signaling events, using lentiviral vectors The system expresses dominant negative VEGFR2 in retinal microvascular endothelial cells, blocking the VEGF/VEGFR2 signaling pathway and inhibiting angiogenesis.

Benefits of technology

Effectively inhibiting VEGF-induced angiogenesis in vitro and in vivo, providing an innovative approach to combat angiogenesis-related diseases, significantly reducing angiogenesis-related cellular events, and demonstrating the prospect of combating angiogenesis-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956969A_ABST
    Figure CN118956969A_ABST
Patent Text Reader

Abstract

The invention discloses a lentiviral vector containing VEGFR2 (vascular endothelial growth factor receptor 2) mutation, application of the lentiviral vector in preparation of medicines for preventing and treating neovascular diseases and a product, and relates to the technical field of biology. The invention provides a lentiviral vector combination. The lentiviral vector combination is prepared from LTR-EF1 alpha-SpCas9n-sRT-U6-epgRNA-LTR and / or LTR-EF1 alpha-MLH1dn-U6-ngRNA-LTR, wherein the LTR-EF1 alpha-SpCas9n-sRT-U6-epgRNA-LTR and / or the LTR-EF1 alpha-MLH1dn-U6-ngRNA-LTR and / or the The sequences are respectively shown as SEQ ID NO: 1 and SEQ ID NO: 2. By transferring the lentivirus combination into primary human retinal vascular endothelial cells, tumor angiogenesis and autophosphorylation of VEGFR2 can be inhibited, and a promising method is provided for resisting angiogenesis-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a lentiviral vector containing a VEGFR2 mutation and its application in preparing a drug for preventing and treating neovascular diseases and a product thereof. Background Art

[0002] Angiogenesis is crucial to a variety of human diseases. Angiogenesis is a complex biological process regulated by angiogenic mediators such as VEGF. VEGF is produced by various cells, including endothelial cells and macrophages, and is associated with a variety of biological activities. It participates in angiogenesis, endothelial cell proliferation, and vascular permeability, and is a key regulator of angiogenesis. In the angiogenesis process, the VEGF family is the main regulatory factor. The VEGF family includes five members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PGF. These are strong angiogenic factors, among which VEGFA plays a key role. VEGFA further stimulates downstream pro-angiogenic pathways such as AKT by binding to the cell surface tyrosine kinase VEGF receptor 2 (VEGFR2), thereby promoting the survival, proliferation, and migration of endothelial cells, ultimately leading to blood vessel formation.

[0003] Angiogenesis is associated with many human diseases, including proliferative diabetic retinopathy. However, a significant number of patients with angiogenesis-related diseases remain resistant to current treatments, including anti-VEGF drugs and VEGFR2 kinase inhibitors.

[0004] Prime editing (PE) is a recently developed genome editing method that offers new avenues for the treatment of human diseases. This system consists of two minimal components: a Cas9 cleavage enzyme (n), such as Streptococcus aureus (Sp)Cas9H840A fused to a reverse transcriptase (RT), and a gene editing guide RNA (pegRNA). However, the efficiency of PE can be improved by adding a structured RNA motif, such as tevopreQ1 (trimmed evopreQ1), to the 3' end of the pegRNA to protect it from degradation. Notably, the pegRNA consists of a single guide RNA (sgRNA), a primer binding sequence (PBS) that is partially complementary to the protospacer region of the DNA, and an RT template containing the desired mutation.

[0005] The primary mechanism of gene editing (PE) is that a gene-editing guide RNA (pegRNA) directs the Cas9 cleavage enzyme-reverse transcriptase (RT) complex to bind to one strand of the target DNA site and cleave the opposing strand near the protospacer adjacent motif (PAM). This cleavage exposes the DNA end of the primer binding sequence (PBS) in the pegRNA, triggering reverse transcriptase (RT) to reversibly transcribe the RT template. As a result, the desired mutation in the RT template is incorporated into the target site in the genome.

[0006] The efficiency of gene editing (PE) can be improved by adding a single guide RNA (sgRNA) to direct the Cas9 cleavage enzyme (Cas9n) to cleave the non-edited strand, and by expressing a dominant-negative DNA mismatch repair (MMR) protein (MLH1dn). Importantly, PE can achieve all types of mutations, such as base pair substitutions and small insertions / deletions (indels), in the genomic DNA of living cells without the need for double-strand DNA breaks (DSBs), and has been successfully used to introduce genetic changes in cultured cells and animal models.

[0007] The present invention aims to provide a lentiviral vector, which is used to infect human retinal microvascular endothelial cells to produce dominant negative VEGFR2, and can inhibit VEGF-induced signal transduction events and angiogenesis under in vitro conditions. Summary of the Invention

[0008] The purpose of the present invention is to provide a method for constructing a lentiviral vector containing a VEGFR2 mutation and its application in preparing drugs for preventing and treating neovascular diseases and products.

[0009] In order to achieve the above-mentioned object of the invention, the technical solution of the present invention is as follows:

[0010] In one aspect, the present invention provides a lentiviral vector combination, comprising LTR-EF1α-SpCas9n-sRT-U6-epegRNA-LTR and / or LTR-EF1α-MLH1dn-U6-ngRNA-LTR;

[0011] The sequence of the LTR-EF1α-SpCas9n-sRT-U6-epegRNA-LTR is shown in SEQ ID NO: 1; the sequence of the LTR-EF1α-MLH1dn-U6-ngRNA-LTR is shown in SEQ ID NO: 2.

[0012] Specifically, the LTR-EF1-SpCas9n-sRT-U6-epegRNA-LTR is lentivirus-epegRNA.

[0013] Furthermore, the lentivirus-epegRNA is derived from lent-crispr v2 by replacing SpCas9 with SpCas9n-sRT and then inserting a synthetic enhanced pegRNA.

[0014] Specifically, the LTR-EF-1-MLH1dn-U6-ngRNA-LTR is lentivirus-ngRNA.

[0015] Furthermore, the lentivirus-ngRNA is derived from lenti-crispr v2 by replacing SpCas9 with MLH1dn and then inserting an ngRNA.

[0016] SEQ ID NO: 1:

[0017]

[0018] aagtcaacaagcgggtggaagacatccaccccaccgtgcccaacccttacaacctcttgagcgggctcccaccgtcccac

[0019] cagtggtacactgtgcttgatttaaaggatgcctttttctgcctgagactccaccccaccagtcagcctctcttcgcctttgagt

[0020] ggagagatccagagatgggaatctcaggacaattgacctggaccagactcccacagggtttcaaaaacagtcccaccctg

[0021] tttaatgaggcactgcacagagacctagcagacttccggatccagcacccagacttgatcctgctacagtacgtggatgact

[0022] tactgctggccgccacttctgagctagactgccaacaaggtactcgggccctgttacaaaccctagggaacctcgggtatc

[0023] gggcctcggccaagaaagcccaaatttgccagaaacaggtcaagtatctggggtatcttctaaaagagggtcagagatgg

[0024] ctgactgaggccagaaaagagactgtgatggggcagcctactccgaagacccctcgacaactaagggagttcctaggga

[0025] aggcaggcttctgtcgcctcttcatccctgggtttgcagaaatggcagcccccctgtaccctctcaccaaaccggggactct

[0026] gtttaattggggcccagaccaacaaaaggcctatcaagaaatcaagcaagctcttctaactgccccagccctggggttgcc

[0027] agatttgactaagccctttgaactctttgtcgacgagaagcagggctacgccaaaggtgtcctaacgcaaaaactgggacct

[0028] tggcgtcggccggtggcctacctgtccaaaaagctagacccagtagcagctgggtggcccccttgcctacggatggtagc

[0029] agccattgccgtactgacaaaggatgcaggcaagctaaccatgggacagccactagtcattctggccccccatgcagtag

[0030] aggcactagtcaaacaaccccccgaccgctggctttccaacgcccggatgactcactatcaggccttgcttttggacacgg

[0031] accgggtccagttcggaccggtggtagccctgaacccggctacgctgctcccactgcctgaggaagggctgcaacacaa

[0032] ctgccttgatatcctggccgaagcccacggaacccgacccgacctaacggaccagccgctcccagacgccgaccacac

[0033] ctggtacacggatggaagcagtctcttacaagagggacagcgtaaggcgggagctgcggtgaccaccgagaccgaggt

[0034] aatctgggctaaagccctgccagccgggacatccgctcagcgggctgaactgatagcactcacccaggccctaaagatg

[0035] gcagaaggtaagaagctaaatgtttatactgatagccgttatgcttttgctactgcccatatccatggagaaatatacagaagg

[0036] cgtgggtggctcacatcagaaggcaaagagatcaaaaataaagacgagatcttggccctactaaaagccctctttctgccc

[0037] aaaagacttagcataatccattgtccaggacatcaaaagggacacagcgccgaggctagaggcaaccggatggctgacc

[0038] aagcggcccgaaaggcagccatcacagagactccagacacctctaccctcctcatagaaaattcatcacccGgatccgg

[0039] cgcaacaaacttctctctgctgaaacaagccggagatgtcgaagagaatcctggaccgaccgagtacaagcccacggtg

[0040] cgcctcgccacccgcgacgacgtccccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgccacgcgc

[0041] cacaccgtcgatccggaccgccacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgtcgggctcgaca

[0042] tcggcaaggtgtgggtcgcggacgacggcgccgcggtggcggtctggaccacgccggagagcgtcgaagcgggggc

[0043] ggtgttcgccgagatcggcccgcgcatggccgagttgagcggttcccggctggccgcgcagcaacagatggaaggcct

[0044] cctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgtcggagtctcgcccgaccaccagggcaagg

[0045] gtctgggcagcgccgtcgtgctccccggagtggaggcggccgagcgcgccggggtgcccgccttcctggagacctccg

[0046] cgccccgcaacctccccttctacgagcggctcggcttcaccgtcaccgccgacgtcgaggtgcccgaaggaccgcgcac

[0047] ctggtgcatgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacctctggattacaaaatttgtgaaagattg

[0048] actggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggct

[0049] ttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgc

[0050] actgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctc

[0051] cctattgccacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattcc

[0052] gtggtgttgtcggggaaatcatcgtcctttccttggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgct

[0053] acgtcccttcggccctcaatccagcggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgcctt

[0054] cgccctcagacgagtcggatctccctttgggccgcctccccgcgtcgactttaagaccaatgacttacaaggcagctgtag

[0055] atcttagccactttttaaaagaaaaggggggactggaagggctaattcactcccaacgaagacaagatctgctttttgcttgta

[0056] ctgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaag

[0057] cttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagca。

[0058] SEQ ID NO:2:

[0059]

[0060] agataaatgggcaagtttgtggaattggtttaacataacaaattggctgtggtatataaaattattcataatgatagtaggaggc

[0061] ttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatcgtttcagacccac

[0062] ctcccaaccccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagacagatcca

[0063] ttcgattagtgaacggatcggcactgcgtgcgccaattctgcagacaaatggcagtattcatccacaattttaaaagaaaagg

[0064] ggggattggggggtacagtgcaggggaaagaatagtagacataatagcaacagacatacaaactaaagaattacaaaaa

[0065] caaattacaaaaattcaaaattttcgggtttattacagggacagcagagatccagtttggttaattaaggtaccgagggcctatt

[0066] tcccatgattccttcatatttgcatatacgatacaaggctgttagagagataattagaattaatttgactgtaaacacaaagatatt

[0067] agtacaaaatacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgctt

[0068] accgtaacttgaaagtatttcgatttcttggctttatatatcttgtggaaaggacgaaacaccgTCATCCAATGGGA

[0069] GTTCATCgttttagagctagaaatagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcg

[0070] gtgcttttttgaattcgctagctaggtcttgaaaggagtgggaattggctccggtgcccgtcagtgggcagagcgcacatcg

[0071] cccacagtccccgagaagttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgcggggtaaactgg

[0072] gaaagtgatgtcgtgtactggctccgcctttttcccgagggtgggggagaaccgtatataagtgcagtagtcgccgtgaac

[0073] gttctttttcgcaacgggtttgccgccagaacacaggaccggttctagagccaccatgagcttcgttgctggagtcatccgg

[0074] agactggacgagacagtggtgaacagaattgccgccggcgaggtgatccagagacctgccaatgcaataaaggagatg

[0075] atcgagaactgtctggacgccaagtccacaagcattcaggtgatcgtgaaggagggcggactgaagctgatccagatcca

[0076] agacaacggcacaggcatcagaaaggaagatctggacatcgtgtgtgaacggttcaccacatctaagctgcagtcttttga

[0077] ggatctggcctctatcagtacctacggcttcagaggcgaggccctggccagcatcagccacgtggcccatgtgaccatca

[0078] ccaccaaaaccgccgacggcaaatgcgcttatcgcgctagctacagcgacggcaagctgaaagccccgccaaagcctt

[0079] gcgccggcaaccagggtacacagataacagtggaggatctgttctacaacatcgccacccggagaaaggccctgaaaaa

[0080] tcccagcgaggagtacggcaagatcctggaagtcgtcggcagatactccgtgcacaacgccggaatcagctttagcgtaa

[0081] agaagcagggagaaaccgtggccgatgtgcgcaccctgccaaatgccagcaccgtggataacatcagaagcattttcgg

[0082] aaatgccgtgtccagagaactgatcgagatcggctgcgaagataagaccctggcttttaagatgaacggctacatcagcaa

[0083] cgccaattactctgtgaagaagtgcatctttcttctgttcatcaaccacagactggtggaaagcaccagcctgcggaaagcc

[0084] atcgagacagtgtacgccgcctacctgcctaagaacacccaccccttcctgtacctgagcctcgagatcagccctcagaac

[0085] gtggacgtcaatgtgcatcctacaaagcacgaggtgcacttcctgcacgaggaaagcatcctggaaagagtgcagcagc

[0086] acattgagagcaagctgctgggctctaaacggacagccgacggaagcgagttcgagtcaccaaagaagaagcggaaag

[0087] tcGAGAGAGAAATTCACCAAGAGACCcatcatcaccatcaccatggatccggcgcaacaaacttctc

[0088] tctgctgaaacaagccggagatgtcgaagagaatcctggaccgaccgagtacaagcccacggtgcgcctcgccacccg

[0089] cgacgacgtccccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgccacgcgccacaccgtcgatcc

[0090] ggaccgccacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtgtgg

[0091] gtcgcggacgacggcgccgcggtggcggtctggaccacgccggagagcgtcgaagcgggggcggtgttcgccgaga

[0092] tcggcccgcgcatggccgagttgagcggttcccggctggccgcgcagcaacagatggaaggcctcctggcgccgcacc

[0093] ggcccaaggagcccgcgtggttcctggccaccgtcggagtctcgcccgaccaccagggcaagggtctgggcagcgcc

[0094] gtcgtgctccccggagtggaggcggccgagcgcgccggggtgcccgccttcctggagacctccgcgccccgcaacctc

[0095] cccttctacgagcggctcggcttcaccgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtgcatgaccc

[0096] gcaagcccggtgcctgaacgcgttaagtcgacaatcaacctctggattacaaaatttgtgaaagattgactggtattcttaact

[0097] atgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctcctt

[0098] gtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgac

[0099] gcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgccacggc

[0100] ggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggg

[0101] gaaatcatcgtcctttccttggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggcc

[0102] ctcaatccagcggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacga

[0103] gtcggatctccctttgggccgcctccccgcgtcgactttaagaccaatgacttacaaggcagctgtagatcttagccacttttt

[0104] aaaagaaaaggggggactggaagggctaattcactcccaacgaagacaagatctgctttttgcttgtactgggtctctctgg

[0105] ttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgct

[0106] tcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagca.

[0107] In another aspect, the present invention provides a lentiviral vector system, comprising the above-mentioned lentiviral vector combination.

[0108] Specifically, the lentiviral vector system further comprises a packaging component.

[0109] Specifically, the lentiviral vector system is a three-plasmid system or a four-plasmid system.

[0110] In another aspect, the present invention provides a method for preparing lentiviral vector particles, comprising the following steps:

[0111] (1) co-transfecting the above-mentioned lentiviral vector, envelope vector and packaging vector into host cells;

[0112] (2) Cultivating the transfected host cells to package the lentiviral vector into lentiviral vector particles, and harvesting the produced lentiviral vector particles.

[0113] Specifically, in step (1), the mass ratio of the lentiviral vector, the envelope vector, and the packaging vector is (20-30): (5-10): (20-25);

[0114] Furthermore, in step (1), the mass ratio of the lentiviral vector, the envelope vector and the packaging vector is 28:7:21.

[0115] Specifically, the envelope vector described in step (1) is a VSV-G envelope vector.

[0116] Furthermore, the packaging vector described in step (1) is psPAX2.

[0117] In another aspect, the present invention provides a lentiviral vector particle prepared using the above method.

[0118] In another aspect, the present invention provides a host cell comprising the aforementioned lentiviral vector combination or the aforementioned lentiviral vector particle.

[0119] Specifically, the host cells include prokaryotic cells and eukaryotic cells.

[0120] Furthermore, the prokaryotic cells include cyanobacteria, bacteria, mycoplasmas and chlamydia, archaea, actinomycetes, rickettsiae, spirochetes, and prokaryotes.

[0121] Furthermore, the eukaryotic cells include plant cells and animal cells.

[0122] Furthermore, the host cell is a eukaryotic cell.

[0123] In another aspect, the present invention provides use of the aforementioned lentiviral vector combination, the aforementioned lentiviral vector particle, or the aforementioned host cell in the preparation of a drug for preventing or treating neovascular diseases.

[0124] Specifically, the neovascular diseases include choroidal neovascular disease, retinal neovascular disease, subretinal neovascular disease, corneal neovascular disease, iris neovascular disease, and neovascular glaucoma.

[0125] Furthermore, the retinal neovascular disease refers to an ocular angiogenesis disease characterized by diabetic retinopathy, retinopathy of prematurity or retinal vein occlusion.

[0126] Furthermore, the choroidal neovascularization disease may refer to wet age-related macular degeneration.

[0127] In another aspect, the present invention provides a pharmaceutical composition for preventing and treating neovascular diseases, wherein the pharmaceutical composition comprises the aforementioned lentiviral vector combination or the aforementioned lentiviral vector particles or the aforementioned host cells.

[0128] Specifically, the pharmaceutical composition may further include pharmaceutically acceptable excipients.

[0129] Furthermore, the pharmaceutically acceptable excipients are selected from one or more of excipients, buffers, emulsifiers, stabilizers, diluents, adhesives, preservatives, lubricants, pH regulators, cryoprotectants, and flavoring agents.

[0130] Specifically, the excipient is selected from at least one of microcrystalline cellulose, lactose, pregelatinized starch, cyclodextrin, carboxymethyl cellulose, mannitol, magnesium stearate, starch, calcium phosphate, ethyl cellulose, methyl cellulose, alginic acid, gelatin, gum arabic, glyceryl monostearate, sodium starch glycolate, guar gum, glycerol, and propylene glycol.

[0131] Specifically, the buffer is selected from at least one of sodium dihydrogen phosphate, sodium bicarbonate, ammonium bicarbonate, sodium acetate, citrate, histidine, and succinate.

[0132] Specifically, the emulsifier is selected from at least one of magnesium stearate, zinc stearate, calcium stearate, glyceryl stearate, sorbitan isostearate, sorbitan oleate, glyceryl oleate, and polyglyceryl-3 polyricinoleate.

[0133] Specifically, the stabilizer is selected from at least one of acacia gum, agar, alginic acid, cellulose ether, and carboxymethyl chitosan.

[0134] Specifically, the diluent is selected from at least one of erythritol, mannitol, sorbitol, xylitol, lactose, sucrose, corn starch, potato starch, calcium phosphate, calcium citrate, and crystalline cellulose.

[0135] Specifically, the binder is selected from at least one of ethanol, starch slurry, syrup, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, sodium alginate, and polyvinyl pyrrolidone.

[0136] Specifically, the preservative is selected from at least one of methylparaben, propylparaben, methylparaben, ethylparaben, propylparaben, chlorobutanol, thimerosal, mercuric cyanide, phenoxyethanol, chlorhexidine, benzoic acid, sodium benzoate, chlorocresol, benzalkonium bromide, benzalkonium chloride, and ethylparaben.

[0137] Specifically, the lubricant is selected from at least one of magnesium stearate, stearic acid, sodium chloride, sodium oleate, sodium lauryl sulfate, and poloxamer.

[0138] Specifically, the pH regulator is selected from at least one of citric acid, fumaric acid, succinic acid, tartaric acid, malic acid and ascorbic acid.

[0139] Specifically, the cryoprotectant is selected from at least one of sucrose, glucose, mannitol, fructose, trehalose, dextrose, lactose, glycerol, methanol, ethanol, ethylene glycol, propylene glycol, dimethyl sulfoxide (DMSO), acetamide or formamide.

[0140] Specifically, the flavoring agent is selected from at least one of sweet orange flavor, vanilla flavor, strawberry flavor, milk flavor, banana flavor, and cherry flavor.

[0141] Specifically, the dosage form of the pharmaceutical composition is drops, mixtures, tinctures, injections, tablets, powders, oral liquids, capsules, granules, ointments, suspensions, powders, emulsions, solutions, pellets, pills, buccal tablets, freeze-dried powder injections, gels, suppositories or aerosols.

[0142] The beneficial effects of the present invention are:

[0143] The present invention provides a lentiviral vector combination, consisting of two lentiviral vectors: (1) LTR-EF1α-SpCas9n-sRT-U6-epegRNA-LTR (lentivirus-epegRNA), and (2) LTR-EF1α-MLH1dn-U6-ngRNA-LTR (lentivirus-ngRNA) (the two are collectively referred to as PE6h).

[0144] The present invention uses the PE6h system to create a VEGFR2 mutation (c.18315T>A) in human retinal microvascular endothelial cells (HRECs), resulting in a premature stop codon, thereby generating a dominant negative VEGFR2 (DN-VEGFR2). This DN-VEGFR2 can inhibit VEGF-induced VEGFR2 activation and its downstream PI3K / Akt and Ras / Raf / Erk signaling pathways, leading to a significant reduction in angiogenesis-related cellular events. Lentivirus-mediated delivery of DN-VEGFR2 to animal models can inhibit tumor angiogenesis. The PE6h system can be used to abolish angiogenesis in vivo because it not only neutralizes VEGF but also inhibits VEGFR2 autophosphorylation. Therefore, PE6h-mediated DN-VEGFR2 expression provides a promising and innovative approach to combating diseases associated with angiogenesis. BRIEF DESCRIPTION OF THE DRAWINGS

[0145] Figure 1 Schematic diagram of the generation of DN-VEGFR2 using PE6h;

[0146] A is a schematic diagram of the dual-directed vector for delivering PE6h: 1) A lentiviral vector containing a DNA sequence for expressing the SpCas9n (H840A) and sRT (short enhancer codon-optimized reverse transcriptase) fusion protein (lentiviral-epegRNA) controlled by the EF (elongation factor)-1α promoter and U6-epegRNA. U6: U6 promoter, LTR: long terminal repeat; 2) A lentiviral vector for expressing MLH1dn controlled by the EF1α promoter and U6-ngRNA. ng: cleaved guide RNA, DN: dominant negative.

[0147] B is a schematic diagram of the generation of the VEGFR2 (K798stop) mutant using PE6h: 1) Schematic diagram of the human VEGFR2 gene locus (NC_000004.12), showing the 798th amino acid residue, lysine (K), for mutation; 2) Schematic diagram of the creation of the VEGFR2 c.18315T>A (K798stop) mutation using PE6h. RT template (16 nucleotides): template for reverse transcription; PBS (14 nt): primer binding sequence; PAM: protospacer adjacent motif, used to generate the protospacer sequence of the sgRNA.

[0148] C is a schematic diagram of full-length VEGFR2 and DN-VEGFR2; full-length VEGFR2 (1356 amino acids, aa): an extracellular domain with 7 IgG domains connected by endogenous disulfide bonds for ligand binding, a transmembrane domain for crossing the cell membrane, and an intracellular domain containing a kinase domain; dominant negative VEGFR2 (DN-VEGFR2, 797 amino acids) has a mutation (K798stop) near the intracellular membrane.

[0149] Figure 2 To generate DN-VEGFR2 in HRECs by PE6h:

[0150] A shows Sanger DNA sequencing analysis of PCR products from the genomic locus of human retinal microvascular endothelial cells (HRECs) transduced with double LVs carrying the PE6h system targeting VEGFR2 or lacZ as a negative control. Point mutations were present in genomic DNA transduced with PE6h targeting VEGFR2 (PE6h-VEGFR2), STOP: stop codon (TAG);

[0151] B, next-generation sequencing (NGS) analysis of PCR products from the HREC genomic locus in A;

[0152] C shows Western blot analysis of lysates from transduced HRECs with the indicated antibodies. Representative images (left) and bar graphs (right) show data for Western blot band intensities (VEGFR2 and β-actin) from three representative experiments. "***" indicates significant differences, p < 0.001 using an unpaired t-test. WT: wild type, DN: dominant negative.

[0153] Figure 3 DN-VEGFR2 created for PE6h reduced VEGF-induced activation of VEGFR2, Akt, and Erk1 / 2;

[0154] A shows immunoblots of lysates from HRECs transduced with PE6h for VEGFR2 or lacZ as a control and stimulated with VEGF-A for 10 minutes after growth factor deprivation. A representative image is shown. R2: VEGFR2. B shows bar graphs of Western blot band intensities (p-VEGFR2 vs. Hsp90α, p-Akt vs. Akt, p-Erk1 / 2 vs. Erk1 / 2) from three representative experiments. "***" indicates significant differences, p < 0.001 using one-way ANOVA.

[0155] Figure 4 DN-VEGFR2 generated for PE6h reduces VEGF-induced proliferation in HRECs transduced with PE6h. Figures are the mean ± standard deviation (SD) of three independent experiments. "***" indicates a significant difference, p < 0.001 using one-way ANOVA.

[0156] Figure 5 DN-VEGFR2 created for PE6h inhibits VEGF-induced migration: Transduced HREC cells were subjected to a wound healing assay. The top panel represents three independent experiments, and the scale bar is 200 μm. Each bar represents the mean ± standard deviation of three independent experiments. "***" indicates a significant difference, p < 0.001 using one-way ANOVA.

[0157] Figure 6 DN-VEGFR2 created for PE6 attenuates VEGF-induced tube formation; this is a tube formation assay with transduced HRECs. The top panel is representative of three independent experiments, and the scale bar is 500 μm. Each bar represents the mean ± SD of three independent experiments. "***" indicates a significant difference, p < 0.001 using one-way ANOVA.

[0158] Figure 7 DNA sequencing analysis of the human VEGFR2 locus targeted by PE6h;

[0159] A shows next-generation sequencing (NGS) analysis of PCR products from genomic loci of human retinal microvascular endothelial cells (HRECs) transduced by double LVs carrying the PE6h system (sgRNA 1: TGCTTTCCAGGCCAATGGAG) targeting VEGFR2 or lacZ as a control;

[0160] B is Sanger DNA sequencing analysis of PCR products from the genomic VEGFR2 locus in 582 HRECs transduced with dual LVs carrying the PE6h system targeting VEGFR2 (sgRNA 2: 583ATGCTTTCCAGGCCAATGGA). Genomic DNA point mutations induced by PE6h targeting VEGFR2 (PE6-VEGFR2) and NGS analysis of PCR products from the genomic locus in HRECs.

[0161] C shows Sanger DNA sequencing analysis of PCR products from the genomic VEGFR2 locus in HRECs transduced with dual LVs harboring the PE6h system targeting VEGFR2 (sgRNA3: ATTGATGCTTTCCAGGCCAA). Genomic DNA transduced with PE6h targeting VEGFR2 (PE6-VEGFR2) shows the presence of point mutations and NGS analysis of PCR products from the genomic locus in HRECs. DETAILED DESCRIPTION

[0162] In order to make the technical means, creative features, purpose and efficacy of the present invention easy to understand, the present invention is further illustrated below in conjunction with specific examples, but the following examples are only preferred embodiments of the present invention, not all. Based on the examples in the implementation manner, other embodiments obtained by those skilled in the art without making creative work are all within the scope of protection of the present invention. In the following examples, unless otherwise specified, the operating methods used are all conventional operating methods, the equipment used are all conventional equipment, and the equipment and materials used in each embodiment are all the same.

[0163] Example 1

[0164] 1.1 Enhanced pegRNAs

[0165] A DNA sequence (TGCTTTCCAGGCCAATGGAGGTTTTAGAGCTAGAAATAGCAAGTTAA AATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTG CGTCTACAGTTCCCCTCCATTGGCCTGGAAAgcaCGCGGTTCTATCTAGT TACGCGTTAAACCAACTAGAAttttt, SEQ ID NO: 3), designated VXPEG1, in the human VEGFR2 genomic locus (NC_000004.12), was used to generate enhanced pegRNA (epegRNA) against Streptococcus pyogenes (Sp) Cas9 (H840A) cleavage enzyme (Cas9n).

[0166] A DNA sequence: TCATCCAATGGGAGTTCATC (SEQ ID NO: 4), designated as VX1, was used to generate ngRNA for editing human VEGFR2 (located 47 bases away from the sgRNA cleavage site), and two other sgRNA sequences (5'-ATGCTTTCCAGGCCAATGGA-3' (SEQ ID NO: 5) and 5'-ATTGATGCTTTCCAGGCCAA-3' (SEQ ID NO: 6)) were tested to select epegRNAs (see Tables 1 and Figure 7 ).

[0167] A control protospacer sequence (5'-TGCGAATACGCCCACGCGAT-3' (SEQ ID NO: 7)) selected from the bacterial lacZ gene was used as the control sequence for control enhanced pegRNA (epegRNA) and ngRNA.

[0168] A lentiviral vector with the structure LTR-EF1-SpCas9n-sRT-U6-epegRNA-LTR (lentivirus-epegRNA) was derived from Lentiviral Crispr v2 (Cat. No. 52961, Addgene) by replacing SpCas9 with SpCas9n-sRT and subsequently inserting a synthetic enhanced pegRNA (epegRNA).

[0169] Another lentiviral vector, with the structure of LTR-EF-1-MLH1dn-U6-ngRNA-LTR (lentivirus-ngRNA), was also derived from lenti-crispr v2 by replacing SpCas9 with MLH1dn and then inserting an ngRNA.

[0170] Table 1 Selection of epegRNA for editing human VEGFR2

[0171]

[0172]

[0173] 1.2 Verification of all DNA constructs using Sanger sequencing

[0174] The ngRNA upstream primer (5'-CACCGTCATCCAAGGGCAGTTCATC-3' (SEQ ID NO: 18)) and downstream primer (5'-AAAC-20nt-C-3', where 20nt is the 20 nucleotides complementary to the upstream primer) were mixed in a 1:1 ratio, boiled at 100°C for 5 minutes, and then cooled naturally for annealing. The ngRNA sequence was digested with BsmBI restriction endonuclease, and ligated into the lentiviral-ngRNA vector using T4 DNA ligase. A primer (5'-GGACTATCATATGCTTACCG-3' (SEQ ID NO: 19) was used for Sanger DNA sequencing.

[0175] PCR primers used for Sanger DNA sequencing and next-generation sequencing (NGS) included: P52F (AATGCACCTAGCTTCAGCCG (SEQ ID NO: 16) and P52R (GGACCACTCTCAAACTCCATGA (SEQ ID NO: 17) for human VEGFR2. Primer synthesis and Sanger sequencing were performed by Qingke Biotechnology Co., Ltd.

[0176] 1.3 Cell culture

[0177] Human embryonic kidney (HEK) 293T cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA) and cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) containing high glucose (4.5 g / L). Primary human retinal microvascular endothelial cells (HRECs) were obtained from Cell Systems (Kirkland, WA) and cultured in Endothelial Growth Medium-2 (EGM-2) provided by Lonza (Walkersville, MD). The above mammalian cells were cultured at 37°C in a humidity-controlled incubator with 5% CO2.

[0178] 1.4 Vector construction

[0179] Lentiviral vector (lentiviral-epegRNA or lentiviral-ngRNA, 28 μg), VSV-G envelope vector (catalog number: 8454, Addgene) (7 μg), and lentiviral packaging vector psPAX2 (catalog number: 12260, Addgene) (21 μg) were mixed in phenol-free DMEM medium (2 ml), and then polyethyleneimine (PEI) solution (220 μl, concentration of 1 μg / μl, Polysciences, 23966-2) was added to each of these mixtures. This mixture was allowed to stand in a fume hood for 15 minutes and then added dropwise to HEK 293T cells at 70% density, which were grown in 150 mm cell culture dishes, and the operation process was as described above.

[0180] 1.5 In vitro transduction of human retinal microvascular endothelial cells

[0181] When HRECs were grown to 80% confluence in 6-well plates, the culture medium was replaced with fresh culture medium and then PE6h (10 μl / well per left chamber) was added to the culture medium containing 5x10e9 ug / m viral genomes containing minivirus particles in the presence of 8 μg / ml polybrene. Transduced cells were then selected with puromycin (1 μg / ml) for 1 week and analyzed by western blot or DNA sequencing.

[0182] 1.6 Protein polyacrylamide gel electrophoresis

[0183] When the transduced HREC cell lines reached 90% confluence, they were cultured in medium without growth factors. Six hours later, they were treated with VEGF (10 ng / ml) for 10 minutes, and the cell lysates were analyzed by Western blotting for their expression.

[0184] 1.7 DNA sequencing

[0185] Genomic DNA was extracted from human human epithelial cells (HRECs) using the QuickExtract DNA Extraction Kit (Lucigen, Cat. No. QE09050). The cell pellet was incubated with QuickExtract solution at 65°C for 6 minutes and then at 100°C for 10 minutes. DNA fragments from the VEGFR2 genomic locus in HRECs were amplified by PCR and used for Sanger DNA sequencing and next-generation sequencing.

[0186] 1.8 Cell proliferation

[0187] Transduced HRECs were cultured in 24-well plates (3 × 10^4 cells per well) using endothelial cell growth medium. After the cells attached to the plates, they were deprived of growth factors (GF) for 7 hours. Subsequently, these GF-deprived cells were treated with or without VEGF (20 ng / ml). After 48 hours, they were trypsinized and counted using a microscope.

[0188] 1.9 Cell Migration

[0189] When transduced cells reached 90% confluence in 24-well plates, their culture medium was replaced with growth factor (GF)-free medium for 7 hours. Adherent cells were then wounded using a sterile 200 μl pipette tip and treated with or without VEGF (20 ng / ml). The wound area was photographed microscopically 18 hours after wounding, quantified using NIH Image J software, and analyzed using Prism 6 software.

[0190] 2 Experimental results:

[0191] 2.1 Preparation of viral vectors for delivery of PE6h

[0192] Lentiviral vectors (LVs) are capable of delivering long nucleotide sequences and can infect actively transcribing cells, including endothelial cells (ECs) in the neovascular network. Therefore, the present invention has developed a dual lentiviral vector system ( Figure 1 A in ), used to deliver PE6h to target the VEGFR2 site in Homo sapiens (NC_00004.12) ( Figure 1 A c.18315T>A mutation is created on the B). This mutation will result in a premature termination codon (TAG) at this site, replacing the original AAG ( Figure 1 B and Figure 1 C in ), and upon translation produces a dominant negative VEGFR2 (DN-VEGFR2) ( Figure 1 C). This DN-VEGFR2 will block the VEGF / VEGFR2 signaling pathway, thereby inhibiting VEGF-induced angiogenesis.

[0193] In the dual lentiviral vector system, one vector is used to express SpCas9n fused to a codon-optimized reverse transcriptase (RT) and an enhanced pegRNA (epegRNA) with a structured RNA sequence (TevopreQ1) (Lentiviral-epegRNA). The other vector is used to express a dominant negative DNA mismatch repair protein (MLH1dn) and a non-guide RNA (ngRNA) (Lentiviral-ngRNA) ( Figure 1A). HEK293T cells were transfected with these two vectors, along with a packaging vector and an envelope vector, to generate lentivirus.

[0194] 2.2 Production of dominant-negative VEGFR2 in endothelial cells with PE6h

[0195] To reveal whether PE6h can produce DN-VEGFR2, we isolated genomic DNA from HRECs transduced with a dual lentiviral vector system (LVs) targeting genomic VEGFR2 or the control gene lacZ for PCR and DNA sequencing.

[0196] The results show that ( Figure 2 and Figure 7 ), a c.18315T>A mutation was detected in the VEGFR2 genomic locus by Sanger DNA sequencing, and the frequency of this mutation was confirmed by NGS to be 50.76%. It is worth noting that this point mutation (TAG, a stop codon) originates from AAG (K798), resulting in the production of DN-VEGFR2, such as Figure 7 As shown in BC.

[0197] Western blotting results showed that a new, smaller VEGFR2 protein band of approximately 88 kilodaltons (kDa) appeared in HRECs transduced with dual lentiviral vectors (LVs) targeting VEGFR2, and the expression of wild-type VEGFR2 was reduced by 48.6±3.2% compared with HRECs transduced with lacZ-targeting vectors. Figure 2 C).

[0198] The above results confirmed that PE6h caused the c.18315T>A mutation in the genomic DNA of HRECs, resulting in the truncation of the translation of full-length VEGFR2 mRNA at a premature stop codon, and thus produced a new truncated protein: dominant negative VEGFR2 (DN-VEGFR2, 88kDa).

[0199] DN-VEGFR2 generated by 2.3PE6h inhibits VEGFR2 activation

[0200] Dominant negative proteins (DNs) can competitively block the activity of their corresponding wild-type proteins. The present invention investigated whether DN-VEGFR2 produced by PE6h can attenuate the function of VEGFR2.

[0201] Therefore, cell lysates of HRECs expressing PE6h and epegRNA-lacZ or -VEGFR2 were treated with VEGF and analyzed by Western blot. Figure 3 As shown, DN-VEGFR2 resulted in a significant decrease in VEGF-induced p-VEGFR2 (79.8±3.5%), p-Akt (76.3±4.8%), and p-Erk (82.5±3.2%).

[0202] 2.4 DN-VEGFR2 generated by PE6h attenuates VEGF-induced angiogenesis in vitro

[0203] Vascular endothelial growth factor (VEGF)-induced VEGFR2 activation triggers a series of cellular events associated with angiogenesis, such as proliferation and migration. Therefore, the present invention evaluated whether dominant negative VEGFR2 (DN-VEGFR2) produced by PE6h can attenuate these cellular events associated with angiogenesis.

[0204] The experimental results are as follows Figure 4-Figure 6 As shown, VEGF stimulation enhanced the proliferation, migration, and tube formation abilities of HRECs, but these abilities were significantly impeded in HRECs transduced with PE6h against VEGFR2, indicating that DN-VEGFR2 generated by PE6h impeded VEGF-induced angiogenesis in HRECs.

[0205] In this study, the PE6h system integrated all these technological advances to improve the efficiency of PE, and the results showed that the editing efficiency of PE6h has exceeded 50% ( Figure 2 ). It is worth noting that because the pegRNA used in this study did not cause mutations in the silencing seed or PAM site, it is able to rebind and cut the edited DNA site, which may lead to the accumulation of unwanted insertions / deletions (indels). However, such indels were less than 0.1% in this study ( Figure 7 ). Therefore, the PE6h system can be used in a wide range of applications.

[0206] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A lentiviral vector combination, characterized in that: The lentiviral vector combination includes LTR-EF1α-SpCas9n-sRT-U6-epegRNA-LTR and / or LTR-EF1α-MLH1dn-U6-ngRNA-LTR; The sequence of the LTR-EF1α-SpCas9n-sRT-U6-epegRNA-LTR is shown in SEQ ID NO: 1; the sequence of the LTR-EF1α-MLH1dn-U6-ngRNA-LTR is shown in SEQ ID NO:

2.

2. A lentiviral vector system, characterized in that: The lentiviral vector system comprises the lentiviral vector combination according to claim 1.

3. A method for preparing lentiviral vector particles, characterized in that: The following steps are involved: (1) co-transfecting a host cell with the lentiviral vector, envelope vector and packaging vector described in claim 1; (2) Cultivating the transfected host cells to package the lentiviral vector into lentiviral vector particles, and harvesting the produced lentiviral vector particles.

4. The method according to claim 3, characterized in that In step (1), the mass ratio of the lentiviral vector, the envelope vector and the packaging vector is (20-30): (5-10): (20-25).

5. The method according to claim 3, characterized in that: Specifically, the envelope vector described in step (1) is a VSV-G envelope vector; and the packaging vector described in step (1) is psPAX2.

6. Lentiviral vector particles prepared according to the method according to any one of claims 3 to 5.

7. A host cell, characterized in that The host cell comprises the lentiviral vector combination according to claim 1 or the lentiviral vector particle according to claim 6.

8. Use of the lentiviral vector combination according to claim 1, the lentiviral vector particle according to claim 6, or the host cell according to claim 7 in the preparation of a drug for preventing and treating neovascular diseases.

9. The use according to claim 8, characterized in that: The neovascular diseases include choroidal neovascular disease, retinal neovascular disease, subretinal neovascular disease, corneal neovascular disease, iris neovascular disease and neovascular glaucoma.

10. A pharmaceutical composition for preventing and treating neovascularization disease, characterized in that: The pharmaceutical composition comprises the lentiviral vector combination according to claim 1 or the lentiviral vector particles according to claim 6 or the host cell according to claim 7.

Citation Information

Patent Citations

  • Double-plasmid system suitable for yeast pilot editing and application

    CN115948449A

  • Bidirectional leading base gene editing system and application thereof

    CN115948461A

  • Guided editor variants, constructs and methods for enhanced guided editing efficiency and precision

    CN117321201A

  • Medicament for blocking abnormal angiogenesis using enhanced pilot editing and preparation method thereof

    CN117717632A